Pfizer Develops Vaxx for Pregnant Women to Immunize Unborn
Nov 7, 2022 13:00:55 GMT -5
Post by schwartzie on Nov 7, 2022 13:00:55 GMT -5
I predict a HUGE increase in miscarriages! 😡😡😡😡😡
Pfizer Develops RSV Vaccine for Pregnant Women to Immunize their Unborn Babies While in the Womb
By Jim Hoft
Published November 7, 2022 at 11:30am
Pharmaceutical company Pfizer is developing a new vaccine given specifically to pregnant women that will immunize an unborn baby while still in the womb. Pfizer claims that their infants will be protected against the respiratory syncytial virus (RSV) after birth.
According to CDC, RSV is a common respiratory virus that usually causes mild, cold-like symptoms. Most people recover in a week or two, but RSV can be serious, especially for infants and older adults. It is the most common cause of bronchiolitis and pneumonia in children younger than 1 year of age in the United States.
“Pfizer Inc. today announced positive top-line data from the Phase 3 clinical trial (NCT04424316) MATISSE (MATernal Immunization Study for Safety and Efficacy) investigating its bivalent RSV prefusion vaccine candidate, RSVpreF or PF-06928316, when administered to pregnant participants to help protect their infants from RSV disease after birth,” Pfizer announced on its website.
“MATISSE is an ongoing randomized, double-blinded, placebo-controlled Phase 3 study designed to evaluate the efficacy, safety, and immunogenicity of RSVpreF against medically attended lower respiratory tract illness (MA-LRTI) and severe MA-LRTI in infants born to healthy women vaccinated during pregnancy,” Pfizer said.
TRENDING: EXCLUSIVE: Interview with Dr. Shiva Ayyadurai on Social Media Censorship and the Deep State's "Limited Hangout" Response and Cover Up
In the Pfizer study, 7,400 pregnant women were randomly assigned to receive a single dosage of RSVpreF or a placebo during the late second to the third trimester of their pregnancy.
Their Phase 3 study findings and proposed next steps for the vaccine are detailed below:
Vaccine efficacy of 81.8% was observed against severe medically attended lower respiratory tract illness due to RSV in infants from birth through the first 90 days of life with high efficacy of 69.4% demonstrated through the first six months of life
The RSVpreF investigational vaccine was well-tolerated with no safety concerns for both vaccinated individuals and their newborns
Results met one of the study protocol’s pre-specified regulatory success criteria, and Pfizer plans to submit its first regulatory application by end of 2022.
If approved, Pfizer’s RSV vaccine candidate could be the first maternal vaccine available to help prevent this common and potentially life-threatening respiratory illness in young infants
Pfizer is currently the only company with an investigational vaccine being prepared for regulatory applications for both infants through maternal immunization and older adults to help protect against RSV
“We are thrilled by these data as this is the first-ever investigational vaccine shown to help protect newborns against severe RSV-related respiratory illness immediately at birth,” said Annaliesa Anderson, Ph.D., Senior Vice President and Chief Scientific Officer, Vaccine Research & Development, Pfizer.
“These data reinforce Pfizer’s resolve to bring our expertise in the research and development of innovative vaccines to address critical public health needs using new approaches and technologies. We look forward to working with the FDA and other regulatory agencies to bring this vaccine candidate to expectant mothers to help protect their infants against severe RSV during their most vulnerable first six months of life, which has the highest burden of RSV illness in infants. We would like to thank the pregnant women who volunteered for this trial, along with their infants, and all the investigators around the world who participated in the study for their contribution to this landmark research.”
This so-called vaccine has been the subject of an online video that has recently gone viral on Twitter.
Watch the video below:
Endpoints News reported:
Pfizer is stopping enrollment in its Phase III MATISSE trial after it met one of two primary endpoints at an interim analysis by the external data monitoring committee. As measured by severe medically attended lower respiratory tract (MA-LRTI) illness through the first 90 days of life, the committee found an efficacy of 81.8% (CI: 40.6%, 96.3%). The number fell to 69.4% over the six-month follow-up period.
The vaccine, dubbed RSVpreF, didn’t meet the bar on the second primary endpoint of lowering any MA-LRTI. Pfizer reported “clinically meaningful” efficacy of 57.1% from birth through the first 90 days of life, then 51.3% over the six-month follow-up.
And it’s not stopping the company from shooting for a BLA filing by the end of this year.
It hasn’t been easy. Novavax’s RSV vaccine candidate flunked a Phase III study back in 2019, and earlier this year GSK halted development of its own program after flagging safety concerns.
Sanofi and AstraZeneca, on the other hand, recently notched an EU approval for their antibody, nirsevimab.
Just like nirsevimab, Pfizer’s RSVpreF was granted a breakthrough therapy designation by the FDA.
link
Pfizer Develops RSV Vaccine for Pregnant Women to Immunize their Unborn Babies While in the Womb
By Jim Hoft
Published November 7, 2022 at 11:30am
Pharmaceutical company Pfizer is developing a new vaccine given specifically to pregnant women that will immunize an unborn baby while still in the womb. Pfizer claims that their infants will be protected against the respiratory syncytial virus (RSV) after birth.
According to CDC, RSV is a common respiratory virus that usually causes mild, cold-like symptoms. Most people recover in a week or two, but RSV can be serious, especially for infants and older adults. It is the most common cause of bronchiolitis and pneumonia in children younger than 1 year of age in the United States.
“Pfizer Inc. today announced positive top-line data from the Phase 3 clinical trial (NCT04424316) MATISSE (MATernal Immunization Study for Safety and Efficacy) investigating its bivalent RSV prefusion vaccine candidate, RSVpreF or PF-06928316, when administered to pregnant participants to help protect their infants from RSV disease after birth,” Pfizer announced on its website.
“MATISSE is an ongoing randomized, double-blinded, placebo-controlled Phase 3 study designed to evaluate the efficacy, safety, and immunogenicity of RSVpreF against medically attended lower respiratory tract illness (MA-LRTI) and severe MA-LRTI in infants born to healthy women vaccinated during pregnancy,” Pfizer said.
TRENDING: EXCLUSIVE: Interview with Dr. Shiva Ayyadurai on Social Media Censorship and the Deep State's "Limited Hangout" Response and Cover Up
In the Pfizer study, 7,400 pregnant women were randomly assigned to receive a single dosage of RSVpreF or a placebo during the late second to the third trimester of their pregnancy.
Their Phase 3 study findings and proposed next steps for the vaccine are detailed below:
Vaccine efficacy of 81.8% was observed against severe medically attended lower respiratory tract illness due to RSV in infants from birth through the first 90 days of life with high efficacy of 69.4% demonstrated through the first six months of life
The RSVpreF investigational vaccine was well-tolerated with no safety concerns for both vaccinated individuals and their newborns
Results met one of the study protocol’s pre-specified regulatory success criteria, and Pfizer plans to submit its first regulatory application by end of 2022.
If approved, Pfizer’s RSV vaccine candidate could be the first maternal vaccine available to help prevent this common and potentially life-threatening respiratory illness in young infants
Pfizer is currently the only company with an investigational vaccine being prepared for regulatory applications for both infants through maternal immunization and older adults to help protect against RSV
“We are thrilled by these data as this is the first-ever investigational vaccine shown to help protect newborns against severe RSV-related respiratory illness immediately at birth,” said Annaliesa Anderson, Ph.D., Senior Vice President and Chief Scientific Officer, Vaccine Research & Development, Pfizer.
“These data reinforce Pfizer’s resolve to bring our expertise in the research and development of innovative vaccines to address critical public health needs using new approaches and technologies. We look forward to working with the FDA and other regulatory agencies to bring this vaccine candidate to expectant mothers to help protect their infants against severe RSV during their most vulnerable first six months of life, which has the highest burden of RSV illness in infants. We would like to thank the pregnant women who volunteered for this trial, along with their infants, and all the investigators around the world who participated in the study for their contribution to this landmark research.”
This so-called vaccine has been the subject of an online video that has recently gone viral on Twitter.
Watch the video below:
Endpoints News reported:
Pfizer is stopping enrollment in its Phase III MATISSE trial after it met one of two primary endpoints at an interim analysis by the external data monitoring committee. As measured by severe medically attended lower respiratory tract (MA-LRTI) illness through the first 90 days of life, the committee found an efficacy of 81.8% (CI: 40.6%, 96.3%). The number fell to 69.4% over the six-month follow-up period.
The vaccine, dubbed RSVpreF, didn’t meet the bar on the second primary endpoint of lowering any MA-LRTI. Pfizer reported “clinically meaningful” efficacy of 57.1% from birth through the first 90 days of life, then 51.3% over the six-month follow-up.
And it’s not stopping the company from shooting for a BLA filing by the end of this year.
It hasn’t been easy. Novavax’s RSV vaccine candidate flunked a Phase III study back in 2019, and earlier this year GSK halted development of its own program after flagging safety concerns.
Sanofi and AstraZeneca, on the other hand, recently notched an EU approval for their antibody, nirsevimab.
Just like nirsevimab, Pfizer’s RSVpreF was granted a breakthrough therapy designation by the FDA.
link
